Cure My Disease

Don't miss your cure!

 Log in / Sign up

PET scan lights up lung scarring to guide treatment

NCT ID NCT06189820

Diagnosis Sponsor: Erasme University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Oct 16, 2026 · Last updated Oct 16, 2026

Summary

Researchers are testing a PET/CT scan that uses a tracer called FAPI to measure fibrotic activity in the lungs of adults with pulmonary fibrosis. The study checks whether lung FAPI uptake drops after patients start anti-fibrotic treatment, and whether those changes match clinical outcomes like lung function decline. About 70 participants will receive the scan, which involves an intravenous tracer injection followed by imaging.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
FAPI PET/CT imaging with 18F-FAPI-74 or 68Ga-FAPI-46 tracer
What this could lead to
If it works, doctors could use FAPI PET/CT scans to see whether anti-fibrotic drugs are slowing lung scarring, helping them adjust treatment sooner.
What could go wrong
The tracer may not reliably measure fibrosis changes, and the small size means results might not apply broadly. PET scans also involve radiation and are not risk-free.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 70 people

The number the study aims to enrol. It can still change while the study runs.

Started

Mar 2023

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults patients with a fibrotic lung disease (idiopathic pulmonary fibrosis (IPF) or non-IPF fibrotic ILD) as defined according to the 2022 ATS/ERS/JRS/ALAT Clinical Practice Guidelines Exclusion Criteria: * Pregnant or nursing patients * Patients with another significant medical condition which, in the investigator's opinion, may interfere with the completion of the study. * Patients with an active lung neoplasm or any active neoplasm for blood samples

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for FAP are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

classic familial adenomatous polyposis idiopathic pulmonary fibrosis pulmonary fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

FAP Idiopathic pulmonary fibrosis Lung fibrosis Pulmonary fibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Medecine

    RECRUITING

    Brussels, 1070, Belgium

More trials for these conditions

Other studies related to the condition(s) this trial covers.